Ruxolitinib for Steroid-Refractory GVHD: The REACH Trials

home / investigator-perspectives / ruxolitinib-for-steroid-refractory-gvhd-the-reach-trials

In this Investigator Perspectives, Yi-Bin Chen, MD discusses the difference between acute and chronic graft versus host disease, the initial therapeutic management of these diseases, and the newly-approved agents for steroid-refractory disease. He also provides his insights regarding future directions and unmet needs for steroid-refractory GVHD.